These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 394758)

  • 1. Immune response to human keratoacanthoma.
    Flannery GR; Muller HK
    Br J Dermatol; 1979 Dec; 101(6):625-32. PubMed ID: 394758
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Detection of an antisquamous antibody in multiple keratoacanthoma.
    Ahmed AR; Sofen H; Saxon A
    Clin Immunol Immunopathol; 1982 Jan; 22(1):20-31. PubMed ID: 6749353
    [No Abstract]   [Full Text] [Related]  

  • 3. Evidence that regression in keratoacanthoma is immunologically mediated: a comparison with squamous cell carcinoma.
    Patel A; Halliday GM; Cooke BE; Barnetson RS
    Br J Dermatol; 1994 Dec; 131(6):789-98. PubMed ID: 7531999
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunological study of keratoacanthomas.
    Tosca A; Varelzidis A; Avgerinou G; Hatzis J; Perissios A; Nicolis G
    Arch Dermatol Res; 1980; 268(2):149-55. PubMed ID: 7000011
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epidermal antigens in experimental keratoacanthoma and squamous cell carcinoma.
    Muller HK; Flannery GR
    Cancer Res; 1973 Sep; 33(9):2181-6. PubMed ID: 4579775
    [No Abstract]   [Full Text] [Related]  

  • 6. CD30+ cells in regressing keratoacanthoma and in non-keratoacanthomatous squamous cell carcinoma.
    Fernandez-Flores A
    Bratisl Lek Listy; 2008; 109(11):508-12. PubMed ID: 19205562
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunological reaction in keratoacanthoma, a spontaneously resolving skin tumor.
    Brown FC; Tan EM
    Cancer Res; 1973 Sep; 33(9):2030-3. PubMed ID: 4579773
    [No Abstract]   [Full Text] [Related]  

  • 8. Regression of melanoma, but not keratoacanthoma, is associated with increased HLA-B22 and decreased HLA-B27 and HLA-DR1.
    Lowes MA; Dunckley H; Watson N; Crotty K; Cooke B; Barnetson RS; Halliday GM
    Melanoma Res; 1999 Dec; 9(6):539-44. PubMed ID: 10661764
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasmacytoid dendritic cell involvement in the host response against keratoacanthoma.
    Abbas O; Hussein L; Kurban M; Kibbi AG
    J Am Acad Dermatol; 2014 Jun; 70(6):1142-5. PubMed ID: 24831321
    [No Abstract]   [Full Text] [Related]  

  • 10. Eruptive keratoacanthoma with spontaneous regression arising from a cervical squamous cell carcinoma patient treated with nivolumab.
    Fujimura T; Lyu C; Tsukada A; Sato Y; Kambayashi Y; Aiba S
    J Dermatol; 2019 May; 46(5):e177-e178. PubMed ID: 30353913
    [No Abstract]   [Full Text] [Related]  

  • 11. Actinic keratoacanthoma. Speculations on the nature of the lesion and the role of cellular immunity in its evolution.
    Lawrence N; Reed RJ
    Am J Dermatopathol; 1990 Oct; 12(5):517-33. PubMed ID: 2244666
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Specific immune response in human skin carcinoma.
    Nairn RC; Guli EP; Nind AP; Muller HK; Rolland JM; Minty CC
    Br Med J; 1971 Dec; 4(5789):701-5. PubMed ID: 4943032
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The spontaneous regression of keratoacanthoma in man.
    Ramselaar CG; van der Meer JB
    Acta Derm Venereol; 1976; 56(3):245-51. PubMed ID: 59511
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of the antigen recognized by mAb GB36 in normal skin and in skin tumours.
    Hofman P; Lacour JP; Emiliozzi C; Staquet MJ; Hsi BL; Rossi B; Ortonne JP
    Br J Dermatol; 1995 Dec; 133(6):874-83. PubMed ID: 8547038
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Corrigendum: Differential Immunoexpression of Inhibitory Immune Checkpoint Molecules and Clinicopathological Correlates in Keratoacanthoma, Primary Cutaneous Squamous Cell Carcinoma and Metastases.
    Lonsdorf AS
    Acta Derm Venereol; 2024 Sep; 104():. PubMed ID: 39233466
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Beta 2 microglobulin expression in keratoacanthomas and squamous cell carcinoma.
    Graham RM; MacFarlane AW; Curley RK; Nash JR
    Br J Dermatol; 1987 Oct; 117(4):441-9. PubMed ID: 3314969
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cases with a spontaneous regression of an infiltrating non-crateriform keratoacanthoma and squamous cell carcinoma with a keratoacanthoma-like component.
    Misago N; Takai T; Murata Y; Nagase K; Narisawa Y
    J Dermatol; 2014 May; 41(5):430-4. PubMed ID: 24628407
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Smooth muscle-associated antigen in experimental cutaneous squamous cell carcinoma, keratoacanthoma, and papilloma.
    Toh BH; Muller HK
    Cancer Res; 1975 Dec; 35(12):3741-5. PubMed ID: 811354
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Keratoacanthoma: the Australian experience.
    Sullivan JJ
    Australas J Dermatol; 1997 Jun; 38 Suppl 1():S36-9. PubMed ID: 10994470
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Histocompatibility antigens and the solitary keratoacanthoma].
    Molochkov VA; Il'in II; Dolgushin II; Kuzina MV
    Vopr Onkol; 1989; 35(3):286-8. PubMed ID: 2523181
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.